Aldevron Launches New Innovation Center in Waltham, MA
"Establishing a presence in Waltham puts Aldevron at the crossroads of scientific discovery.' - Venkta Indurthi, CSO of Aldevron
Share
The new Waltham site is designed to fast-track advancements in the manufacture of DNA, RNA and proteins for advanced therapies, expanding Aldevron's capabilities in cell-free DNA, molecular biology, gene editing, and mRNA analytics. By establishing a base in the Boston area, Aldevron is positioning itself at the epicenter of biotech innovation—enabling closer collaboration with clients, faster project timelines and enhanced support for the development of advanced therapies.
'Establishing a presence in Waltham puts Aldevron at the crossroads of scientific discovery,' said Venkata Indurthi, Chief Scientific Officer at Aldevron. 'This Innovation Center is a launchpad for transformative research, empowering us to innovate, collaborate and grow alongside the brightest minds in biotech.'
The Waltham Innovation Center will complement Aldevron's established scientific teams in Fargo, ND, and Madison, WI, and will serve as a catalyst for recruiting top talent from Boston's vibrant biotech community.
'Our recent role in the groundbreaking 'Baby KJ' CRISPR therapy delivery demonstrates the life-changing impact that comes from investing in innovation,' said Jennifer Meade, President of Aldevron. 'As one of the most established biotech partners in the U.S., this expansion is a natural evolution—opening new opportunities for growth, deeper client partnerships and greater support for the scientists shaping the future of medicine.'
About Aldevron
Founded in 1998, Aldevron is a global leader in enabling the development of next-generation genomic medicines. As part of Danaher Corporation, Aldevron empowers scientists and innovators worldwide to advance transformative therapies that are redefining the future of medicine. Aldevron's expertise and integrated solutions have supported landmark achievements—including playing a key role in manufacturing the world's first mRNA-based personalized CRISPR therapy. With facilities in Fargo, ND, Madison, WI and Waltham, MA, Aldevron is at the forefront of accelerating scientific discovery and expanding the possibilities of gene editing, gene therapy and other breakthrough modalities. By partnering with leading researchers and organizations, Aldevron is helping to turn the promise of genomic medicine into reality for patients around the globe.
To learn more about how Aldevron is advancing biological science, visit www.aldevron.com/about-us and follow the company on LinkedIn, Facebook and YouTube.
ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
17 hours ago
- Business Wire
Terra Firma Energy Welcome UK Government Consultation on Hydrogen Blending into Great Britains Gas Transmission Network
LONDON--(BUSINESS WIRE)--At Terra Firma Energy, we welcome the UK Government's consultation into the blending of Hydrogen into Britain's Gas Transmission Network as a timely and positive step forward for both the UK's decarbonisation goals and the future of flexible power generation. All our projects are engineered to be hydrogen-ready from the outset, ensuring long-term operational flexibility and resilience in a rapidly evolving energy landscape. By anticipating changes in fuel supply and regulatory frameworks, we have future-proofed our generation assets to adapt quickly to low-carbon solutions like hydrogen blending. The ability to support hydrogen integration, even at early-stage blend levels, reinforces our commitment to sustainable innovation and positions our portfolio to contribute meaningfully to a net zero grid. Terra Firma Energy welcome UK Government Consultation on Hydrogen Blending into Great Britains Gas Transmission Network. Share The Department for Energy Security and Net Zero (DESNZ) has launched a new consultation exploring the potential for blending low-carbon hydrogen into Great Britain's gas transmission network. Following previous consultations on hydrogen blending into local distribution networks, the government is now seeking views on whether introducing hydrogen at the transmission level - the high-pressure National Transmission System (NTS) - could offer strategic and economic value. A Step Toward Net Zero Hydrogen is seen as a key player in the UK's push to reach net zero emissions by 2050. Blending low-carbon hydrogen with natural gas could offer a transitional path, supporting early-stage hydrogen production while reducing the carbon intensity of the existing gas network. DESNZ is currently evaluating whether to enable blending of up to 2% hydrogen by volume into the NTS. This small percentage could act as an 'off-taker of last resort' for hydrogen producers, providing a backup market when dedicated customers are not available. Balancing Innovation with Risk The consultation outlines both the potential benefits and challenges. While hydrogen blending could support the growth of the hydrogen economy and help manage electricity system constraints, it also raises concerns for industrial users connected to the transmission system. Many of these users rely on stable, high-quality gas supplies, and even a 2% hydrogen blend could affect equipment performance, increase costs, or require infrastructure upgrades. Terra Firma Energy have been proactive in ensuring all our projects have been built utilising hydrogen ready generation sets that can accommodate a 20% blend of hydrogen into the network. Studies cited in the consultation show that most transmission-connected users could technically handle a 2% blend with minimal changes, though feasibility studies and equipment modifications may still be necessary. At higher blends (5% or 20%), the risks and costs escalate significantly. Cross-Border Considerations The UK's ability to blend hydrogen is also influenced by developments in the EU. Under the EU Hydrogen and Decarbonised Gas Market Package, Member States can blend up to 2% hydrogen by volume, but are not required to do so. This creates potential interoperability issues with the UK's gas inter-connectors to Ireland, Belgium, and the Netherlands - especially if hydrogen blends exceed that threshold.
Yahoo
a day ago
- Yahoo
CRISPR Therapeutics (CRSP) Sees 47% Price Increase Over Last Quarter
CRISPR Therapeutics recently announced significant developments in its in vivo cardiovascular disease programs, notably CTX310 and CTX320, which may have contributed to the company's 47% share price increase over the last quarter. The company's inclusion in multiple indices further enhances its market presence, potentially impacting investor interest positively. Meanwhile, CRISPR reported a net loss in its Q1 earnings, although revenue increased year-over-year. Despite a volatile market backdrop, characterized by declining major indices due to weak job reports and tariff concerns, CRISPR's advancements in therapeutic programs and strategic index additions contrasted against broader market movements. We've spotted 1 risk for CRISPR Therapeutics you should be aware of. Uncover the next big thing with financially sound penny stocks that balance risk and reward. Over the past year, CRISPR Therapeutics reported a total shareholder return of 9.74%. While the company's shares outperformed the US Biotechs industry, which returned a decline of 8.4% over the same period, it lagged behind the broader US Market's 17.7% return. The favorable performance relative to its industry can be linked to its strategic advancements in cardiovascular disease programs and inclusion in various Russell indices. The recent developments highlighted in the introduction, particularly the positive updates in CRISPR's cardiovascular programs and index additions, could potentially influence expectations around future revenue and earnings. Analysts forecast strong revenue growth of 57.3% annually, despite the company's forecast to remain unprofitable over the next three years. Meanwhile, with the current share price at $56.09, the market seems to discount the consensus analyst price target of $80.91, reflecting a substantial perceived upside potential in the stock. This price movement suggests that investors might see potential growth opportunities, even as the company navigates its profitability challenges. The valuation report we've compiled suggests that CRISPR Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
a day ago
- Yahoo
UnitedHealth Group Announces Changes to Leadership Team
July 31, 2025--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date. "Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group," said Stephen J. Hemsley, company chairman and chief executive officer. "John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission," said Hemsley. "I look forward to his continued insights as UnitedHealth Group moves forward." DeVeydt, 55, most recently has been a managing director and operating partner at Bain Capital, working with client leaders on operational improvement and growth acceleration. From 2018-2020, he was chairman and CEO of Surgery Partners, Inc. in Nashville, expanding the operational scale and financial performance of the surgical services firm. He joined Anthem, Inc. (now Elevance) in 2005 and served as its chief financial officer from 2007 to 2016. Prior to joining Anthem, DeVeydt served as a partner with PricewaterhouseCoopers LLP, with a focus on the health care sector. "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team," said DeVeydt. "I've been fortunate to know John Rex for over two decades and am honored to follow a leader of his caliber." Rex, 63, joined UnitedHealth Group as chief financial officer of the company's then newly established Optum business and previously had spent his career focused in health care across multiple roles and sectors. "This pivotal moment for UnitedHealth Group is the right time for a new yet greatly experienced executive like Wayne DeVeydt, and I look forward to supporting him and the entire leadership team while continuing to advise on a range of matters," said Rex. About UnitedHealth Group UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn. View source version on Contacts Media: uhgmedia@ UnitedHealth Group Media Sign in to access your portfolio
